GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » Asset Turnover

Sunesis Pharmaceuticals (FRA:RYIS) Asset Turnover : 0.00 (As of Dec. 2020)


View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Sunesis Pharmaceuticals's Revenue for the three months ended in Dec. 2020 was €0.00 Mil. Sunesis Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2020 was €21.45 Mil. Therefore, Sunesis Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2020 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Sunesis Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2020 was -85.06%. It is also linked to ROA % through Du Pont Formula. Sunesis Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2020 was -73.66%.


Sunesis Pharmaceuticals Asset Turnover Historical Data

The historical data trend for Sunesis Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Asset Turnover Chart

Sunesis Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.02 0.01 0.08 -

Sunesis Pharmaceuticals Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 - - - -

Competitive Comparison of Sunesis Pharmaceuticals's Asset Turnover

For the Biotechnology subindustry, Sunesis Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunesis Pharmaceuticals's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Sunesis Pharmaceuticals's Asset Turnover falls into.



Sunesis Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Sunesis Pharmaceuticals's Asset Turnover for the fiscal year that ended in Dec. 2020 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2020 )/( (Total Assets (A: Dec. 2019 )+Total Assets (A: Dec. 2020 ))/ count )
=0.099/( (33.516+19.109)/ 2 )
=0.099/26.3125
=0.00

Sunesis Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2020 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2020 )/( (Total Assets (Q: Sep. 2020 )+Total Assets (Q: Dec. 2020 ))/ count )
=0/( (23.8+19.109)/ 2 )
=0/21.4545
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Sunesis Pharmaceuticals  (FRA:RYIS) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Sunesis Pharmaceuticals's annulized ROE % for the quarter that ended in Dec. 2020 is

ROE %**(Q: Dec. 2020 )
=Net Income/Total Stockholders Equity
=-15.804/18.58
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-15.804 / 0)*(0 / 21.4545)*(21.4545/ 18.58)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.1547
=ROA %*Equity Multiplier
=-73.66 %*1.1547
=-85.06 %

Note: The Net Income data used here is four times the quarterly (Dec. 2020) net income data. The Revenue data used here is four times the quarterly (Dec. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Sunesis Pharmaceuticals's annulized ROA % for the quarter that ended in Dec. 2020 is

ROA %(Q: Dec. 2020 )
=Net Income/Total Assets
=-15.804/21.4545
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-15.804 / 0)*(0 / 21.4545)
=Net Margin %*Asset Turnover
= %*0
=-73.66 %

Note: The Net Income data used here is four times the quarterly (Dec. 2020) net income data. The Revenue data used here is four times the quarterly (Dec. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Sunesis Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Traded in Other Exchanges
N/A
Address
395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines